WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013148316) BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/148316    International Application No.:    PCT/US2013/032082
Publication Date: 03.10.2013 International Filing Date: 15.03.2013
IPC:
C07K 14/495 (2006.01)
Applicants: BIOGEN IDEC MA INC. [US/US]; 14 Cambridge Center Cambridge, Massachusetts 02142 (US).
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin St. 5th Floor Oakland, California 94607-5200 (US)
Inventors: VIOLETTE, Shelia M.; (US).
SHEPPARD, Dean; (US)
Agent: BRENNAN, Jack; Fish & Richardson P.C. P.O. Box 1022 Minneapolis, Minnesota 55440-1022 (US)
Priority Data:
61/617,451 29.03.2012 US
61/648,199 17.05.2012 US
Title (EN) BIOMARKERS FOR USE IN INTEGRIN THERAPY APPLICATIONS
(FR) BIOMARQUEURS UTILISABLES DANS DES APPLICATIONS DE TRAITEMENT PAR L'INTÉGRINE
Abstract: front page image
(EN)The present invention relates to biomarkers for use in determining the sensitivity of patients to therapy with αvβ6 integrin inhibition or therapy with TGF-β pathway inhibitors. The biomarker profiles disclosed herein provide individualized gene and protein profiles which will aid in treating diseases and disorders which are amenable to treatment with therapies designed against αvβ6-integrin and/or TGF-β pathway inhibitors.
(FR)L'invention concerne des biomarqueurs utilisables pour déterminer la sensibilité de patients à un traitement par inhibition de l'intégrine αvβ6 ou à un traitement par des inhibiteurs de la voie du TGF-β. Les profils des biomarqueurs de l'invention comprennent des profils géniques et protéiques individualisés qui contribuent au traitement de maladies et de troubles sensibles à des thérapies mises au point contre l'intégrine αvβ6 et/ou les inhibiteurs de la voie du TGF-β.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)